Bladder Cancer Clinical Trial
Urine-based Molecular Testing vs Cystoscopy for Surveillance of Nonmuscle Invasive Bladder Cancer (NMIBC)
Summary
The purpose of this study is to evaluate patient-reported preference for CxBladder Monitor compared to cystoscopy for patients on surveillance for Nonmuscle Invasive Bladder Cancer (NMIBC).
Eligibility Criteria
Inclusion Criteria:
Male or female with a history of histologically confirmed stage 0 [Ta and/or carcinoma in situ (CIS)] nonmuscle invasive bladder cancer (NMIBC) who have at least 6 months of disease-free survival from last recurrence.
Able to provide urine for testing and comply with study protocol.
Have an email address and be willing to complete surveys online.
Exclusion Criteria:
History of non-urothelial bladder cancer (primary squamous, adenocarcinoma, and small cell carcinoma)
Patients with predominant (>50%) variant histology
Patients with a history of upper tract and/or urethral cancer
Patients with a history of T1 NMIBC
Women who are pregnant
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Scottsdale Arizona, 85259, United States More Info
Principal Investigator
How clear is this clinincal trial information?